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ABSTRAK 
 
Prevalens Expresi Berganda Di Kalangan Pesakit Dewasa DLBCL Dan Factor –Factor Yang 
Berkaitan Dengannya Berserta Kesan Rawatan Di Hospital Universiti Sains Malaysia Dari 
Tahun 2004 Sehingga 2015. 
 
Latar belakang dan Objektif:  
Diffuse Large B-Cell Lymphoma (DLBCL) merupakan penyakit yang kompleks. Rawatan piawai 
(RCHOP) gagal memberi kesan rawatan yang optimum justeru menyumbang kepada prognosis 
yang teruk. Tujuan  kajian ini adalah untuk menentukan prevalens Expresi Berganda di kalangan 
pesakit dewasa DLBCL dan juga bagi menentukan factor –factor yang berkaitan dengannya, di 
samping kesan rawatannya terhadap rawatan piawai. 
  
Metod:  
Kami melakukan kajian rekod retrospektif yang melibatkan pesakit DLBCL dewasa 2004-2015 di 
Hospital Universiti Sains Malaysia. Maklumat demografi, klinikal dan makmal diekstrak daripada 
rekod perubatan, manakala status ekspresi berganda diekstrak daripada pangkalan data 
jabatan histopatologi. 
 
Keputusan:  
Sejumlah 27 pesakit DLBCL telah direkrut dalam kajian ini. Prevalensi Ekspresi berganda adalah 
59.3%. Ia tiada kaitan signifikan dengan kesan rawatan awal semasa penilaian interim (p = 
xi 
 
0.182), tetapi berkait secara signifikan dengan kadar kesembuhan yang rendah terhadap 
rejimen RCHOP (p = 0.002). Expresi Berganda hanya berkaitan secara signifikan dengan tahap  
LDH (p = 0.015). Tiada kaitan yang signifikan antara umur, jantina, etnik, peringkat penyakit, 
gejala B, status ECOG, IPI tersemak, nodal, penglibatan sumsum tulang dan saraf dengan 
Fenotip Expresi Berganda. 
 
Kesimpulan:  
Prevalens Expresi berganda adalah 59.3%. Pesakit dengan Fenotip Ekspresi Double dikaitkan 
dengan peluang yang lebih rendah untuk mencapai Respon Lengkap dengan rejimen RCHOP. Di 
antara pemboleh ubah yang dipilih, tahap LDH yang tinggi kekal sebagai faktor penting yang 
berkaitan dengan Fenotip Ekspresi Double 
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ABSTRACT 
 
THE PERIOD PREVALENCE OF DOUBLE EXPRESSION DIFFUSE LARGE B-CELL LYMPHOMA  
PATIENTS AND ITS ASSOCIATED RISK FACTORS AND TREATMENT RESPONSE IN HOSPITAL 
UNIVERSITI SAINS MALAYSIA FROM YEAR 2004 TO 2015. 
 
Background and Objective:  
Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous and complex disease. Its protein 
expression of MYC and BCL2 and/or BLC6 (Double Expression) is associated with poor response 
to standard treatment, thus poor prognosis. The aim is to determine the period prevalence of 
Double Expression phenotype in DLBCL patients and also its associated risk factors and 
treatment response 
 
Methods:  
We performed a retrospective record review involving adult DLBCL patients from 2004 to 2015 
in Hospital Universiti Sains Malaysia. Demographic, clinical and laboratory information were 
extracted from medical record, whereas double expression status was extracted from 
histopathology department database. 
 
Results:  
A total of 27 DLBCL patients were recruited in this study. The period prevalence of Double 
Expression Phenotypes was 59.3%. It was not significantly associated with early response during 
interim assessment (p=0.182); but was significantly associated with non-complete response 
xiii 
 
rate toward RCHOP regimen (p=0.002). It only significantly associated with serum LDH level 
(p=0.015). There was no significant association between age, gender, ethnicity, stages, B 
symptoms, ECOG status, revised IPI, Extra-nodal, CNS and bone marrow involvement with 
Double Expression phenotype.  
 
Conclusion: 
The period prevalence of Double Expression Phenotypes was 59.3%. Patients with Double 
Expression Phenotypes were associated with lower chance to achieve Complete Response with 
RCHOP regimen. Among the selected variables, raised serum LDH remained the significant 
factor associated with Double Expression Phenotypes. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Diffuse Large B-Cell Lymphoma (DLBCL) 
DLBCL is the commonest form of Non Hodgkin Lymphoma (NHL), comprising 30-40% 
of total NHL cases (WHO, 2008). Recent advancement of genetic analysis had 
revealed its heterogeneity and complexity. Based on cell of origin (COO) 
classification, DLBCL can be divided into germinal center B-cell (GCB) subtype and 
activated B-cell (ABC) subtype. Each subtype has different pathology, prognosis, and 
treatment plan. 
 
DLBCL has an aggressive course of disease progression, usually evolves within 
months. Without treatment, it may lead to symptomatic diseases and death. It may 
present with swelling of lymph nodes (either centrally or periphery) and B 
symptoms, which consist of loss of weight of 10% in 6 months, fever and night 
sweat. Other symptoms depend on site of lymphoma.  
 
DLBCL is diagnosed via excisional or incisional biopsy of tissues. Biopsy obtained is 
sent for immune-phenotyping and cytogenetic analysis. Cytogenetic Fluorescence In 
Situ Hybridization (FISH) studies enable us to detect genetic rearrangement of DLBCL 
with MYC plus BCL2 or BCL 6, also called as Double Hit Lymphoma.  
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Double Hit means presence of concurrent MYC and BCL2/6 gene rearrangement, 
whereas Double Expression means over expression of MYC and BCL2/6 detected via 
immunohistochemistry staining (Phan RT, 2004).   
 
Double Hit usually belongs to GCB subtype whereas Double Expression is seen in 
both ABC and GCB subtypes. Both have similar presenting characteristics, associated 
with advanced stage, extra-nodal disease, poor performance status and high 
International Prognostic Index (IPI). These characteristics lead to poor prognosis to 
standard treatment (Allison Rosenthal, 2016).  
 
The most commonly used initial therapy is rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisone(R-CHOP). Despite major advances in the 
treatment, particularly with the addition of the anti-CD20 monoclonal antibody 
(Rituximab), 40% of the patients still experience early treatment failure after initial 
response to chemotherapy (Catherine T, 2013).  
 
 
1.2 Double Expresser Phenotypes 
DLBCL may harbor some chromosomal breakpoint affecting the MYC/8q24 locus in 
combination with other breakpoint which are BCL2/t(14;18)(q32;q21) and BCL6 
(Kieron D, 2014). MYC expression is associated with uncontrolled cell growth, 
division, and metastasis (Adhikary S, 2005). BCL2 is an anti-apoptotic gene which 
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may extend cell survival (Korsmeyer SJ, 1992). BCL6 encodes a transcriptional 
repressor and when overexpressed can down regulate several genes, which may 
subsequently allow DNA-damaged cells to escape from apoptosis (Phan RT, 2004). 
 
Over the past few years, several studies have identified that a significant proportion 
of DLBCL cases have high protein expression of MYC and BCL2, but frequently 
without translocations via immunohistochemistry (Johnson NA, 2012). It is 
recognized that MYC, BCL2 and BCL6 can be activated through various mechanisms, 
leading to high expression of these protein products (Kieron D, 2014). Recent studies 
identified 20-40% of DLBCL patients have high MYC and BCL2/6 protein co-
expression, detected by IHC (Perry AM, 2014). 
 
High MYC/BCL2 co-expression was associated with an aggressive clinical course and 
inferior outcome after standard RCHOP chemotherapy (Shimin Hu, 2013). Median 
survival are often in months, with most reported to be no more than 1.5 years and 
with overall survivals at 3 or 5 years shorter than expected with usual DLBCL (Pillai 
RK, 2013). 
 
1.3 Protein Expression Detection 
There are many methods used for protein detection, e.g. Enzyme-linked 
Immunosorbent Assay (ELISA), Gel Electrophoresis, Western blot, 
Immunoprecipitation, Spectrophotometry, Immunohistochemistry and etc.  
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Immunohistochemistry method was used for MYC, BCL2 and BCL6 protein detection 
in Histopathology Department Database under the Study “The Immunohistochemical 
Profile of Double-Hit Diffuse Large B-Cell Lymphoma and Their Association with 
Clinicopathological Parameters: A Pilot Study in Hospital” by WN Najmiyah et al 
(2016). Double Expression status in this study was extracted from this database.  
 
1.3.1 Immunohistochemistry  
IHC is used to detect Lymphoma protein expression via primary antibody 
(monoclonal antibody) staining.  
 
1.3.1.1 Tissue Processing 
The selected single representative block for each case was sectioned to 3-micron 
thickness and mounted on commercially available poly-L-lysine pre-coated slides. All 
cases were stained with H&E, re-evaluated their histopathological diagnosis and 
ensure adequate tumor tissues were present for immunohistochemistry staining.   
 
1.3.1.2 Primary Antibodies  
BCL6 primary antibody that was used in this study is clone PG-B6P, whereas BCL 2 
primary antibody that was used in this study is clone 124. Both were manufactured 
and marketed by DAKO Denmark A/S. These antibodies were monoclonal antibody 
that derived from a mouse. Human tonsil was used as positive control. Anti-c-MYC 
primary antibody that was used in this study was clone Y69 (catalog No. AB32072) 
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manufactured and marketed by Abcam, Cambridge, MA. This antibody derived from 
rabbit. Human colonic adenocarcinoma tissue was used as positive control. 
 
1.3.1.3 Immunohistochemical Staining Method 
Each antigen had a preferred method of antigen retrieval, and each antibody had an 
optimal dilution. These optimizations include antigen retrieval, primary antibody 
concentration and detection. After optimization, the procedures of IHC staining for 
BCL2 and MYC (except BCL 6) were described below: 
a) Sectioning 
The selected tissue paraffin blocks were sectioned at 3 microns using microtome. 
The ribbons of the sections were floated in water-bath at temperature of 50°C. 
Then they were fished and mounted onto the poly-L-lysine treated glass slide. 
The slides were allowed to dry on the slide-drying stand at room temperature.  
b) Deparaffinization and hydration 
The slides then were placed on a hot-plate at temperature of 60°C for an hour. 
These steps were important for tissue adherence and to avoid peeling. Hydration 
process began with immersion into Xylene I and II at 5 minutes each. This 
followed by immersion into 100% concentrated alcohol twice at 2 minutes each. 
Subsequently, they are immersed into alcohol with reducing concentration from 
95%, 80%, 70% to 50%. Each of the processes was done at 2 minutes intervals. 
The slides then were rinsed in distilled water.  
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c) Antigen retrieval 
Buffer solution used for heat induced-epitope retrieval (HIER) in BCL2 and MYC 
was Tris buffer, 1mmol/L EDTA, pH9.0. The antigen retrieval was done using 
pressure cooker method. Once the buffer boils, the slides were transferred into 
the pressure cooker and heated for 3 minutes. The pressure cooker then was 
cooled under running water for 15 minutes followed this. The slides were then 
rinsed using distilled water for 5 minutes. 
d) Endogenous peroxidase blocking 
The slides were soaked with 3% Hydrogen peroxidase (H2O2) for 5 minutes then 
rinsed with Tween 20 buffer. This step allowed the endogenous peroxidase 
activity to neutral and reduced the background staining. 
e) Incubation with primary antibody  
BCL2 and MYC primary antibody at dilution of 1:50, 1:50, 1:50, 1:500 and 1:50 
respectively were applied to the sections and incubated for 1 hour at room 
temperature. This was followed by rinsing twice using TrisBuffer Saline (TBS). 
f) Incubation with Horseradish peroxidase (HRP) polymer solution 
Two drops of the HRP secondary antibody were applied onto the sections and 
were incubated for an hour at room temperature. Sections were then rinsed 
twice using TBS.  
g) Chromogen application 
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One drop of 3, 3’-diaminobenzidine (DAB) from DAKO chromogen was applied to 
the sections and incubated for a minute at a room temperature. The sections 
were then rinsed with distilled water. 
h) Counterstaining 
The sections were counter-stained with haematoxylin for 10 seconds and washed 
in running water for 3 minutes before commencing the hydration processes. 
i) Dehydration 
This process was the reverse process of hydration. The sections were immersed 
in alcohol with gradual increased in concentration, from 70% to 80%, twice in 
95% and twice in 100% at 1-minute interval each. This was followed by dipping 
into 2 changes of xylene at 2 minutes each.  
j) Mounting 
The final process was mounting the tissue section using Cytoseal and protect 
with cover slips. 
 
The procedure of IHC staining for BCL 6 is as described below: 
a) Sectioning 
The selected tissue paraffin blocks were sectioned at 3 microns using microtome. 
The ribbons of the sections were floated in water-bath at temperature of 50°C. 
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Then they were fished and mounted onto the poly-L-lysine trated glass slide. The 
slides were allowed to dry on the slide-drying stand at room temperature.  
b) Deparaffinization and hydration 
These slides were placed on a hot-plate at temperature of 60°C for an hour. 
Hydration process began with immersion into Xylene I and II at 5 minutes each. 
This followed by immersion into 100% concentration of alcohol twice at 2 
minutes each. Subsequently, immersed into alcohol with reducing concentration 
from 95%, 80%, 70% to 50%. All these processes were done at 2 minutes 
intervals. The slides were then rinsed in distilled water.  
c) Antigen retrieval 
Buffer solution used for heat induced-epitope retrieval (HIER) in BCL6 is Tris 
buffer, 1mmol/L EDTA, pH9.0. The antigen retrieval was done using pressure 
cooker and was put on hotplate. Once the buffer boiling, the slides were 
transferred inside the pressure cooker and cook for 3 minutes. This was followed 
by cooling for 20 minutes. When cooled, the slides placed in TBS with 0.05% 
Tween 20.  
d) Incubation with primary antibody  
BCL6 primary antibody at dilution of 1:40 was applied to the sections and 
incubated for 30 minutes at room temperature. Sections were rinsed twice using 
TrisBuffer Saline (TBS). 
e) Endogenous peroxidase blocking 
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These slides were soaked with 3% Hydrogen peroxidase (H2O2) for 5 minutes and 
rinsed with Tween 20 buffer.  
f) Incubation with DAKO Mouse Linker 
DAKO Mouse Linker was applied to the sections and incubated for 20 minutes. 
The sections were rinsed twice using TrisBuffer Saline (TBS).  
g) Incubation with Horseradish peroxidase (HRP) polymer solution 
Two drops of HRP secondary antibody were applied onto the sections and 
incubated for an hour at room temperature. Sections were rinsed twice using 
TBS later.  
h) Chromogen application 
One drop of DAB or 3, 3’-diaminobenzidine from DAKO chromogen was applied 
to the sections and incubated for a minute at a room temperature. These 
sections were rinsed with distilled water later. 
i) Counterstaining 
The sections were counter-stained with haematoxylin for 10 seconds and washed 
in running water for 3 minutes before the dehydration processes. 
j) Dehydration 
The sections were immersed in alcohol with gradual increased in concentration, 
from 70% to 80%, twice in 95% and twice in 100% at 1-minute interval each. This 
was followed by dipping into 2 changes of xylene at 2 minutes each.  
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k) Mounting 
The final process was mounting the tissue section using Cytoseal and protect 
with cover slips. 
 
1.3.1.4 Interpretation  
The staining pattern for MYC protein and BCL6 was distinctly nuclear, whereas 
staining BCL2 protein showed a well-defined cytoplasmic staining pattern. In this 
study, the cut point of dichotomizing expression of MYC and BCL2 were ≥40% and 
≥50%, respectively in accordance to the previously established cutoff points 
(Johnson et al., 2012; Savage et al., 2016). The cut point of dichotomizing expression 
of BCL6 was >50% based on previously established cutoff point (Ye et al., 2016). 
These cases are classified as double expression if it has MYC/BCL2 or MYC/BCL6. 
 
1.4 International Prognostic Index (IPI) 
International Prognostic Index Study was published in year 1993 (James OA, 2005). 
This study showed 5 factors with roughly equal power in predicting treatment 
outcome and prognosis. These are: 
1. Age > 60 years 
2. Ann Arbor stage III/IV 
3. More than 1 extra-nodal site  
4. Serum LDH above normal  
5. ECOG performance status ≥2  
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With that, patients may be divided into 4 groups of low risk (score of 0-1), low 
intermediate risk (score of 2), high intermediate risk (score of 3) and high risk (score 
of 4-5). Thus predicting the prognosis in term of 5 years overall survival and 
complete remission rate (James OA, 2005).  
 
However, with the introduction of Rituximab in Standard Chemotherapy regimen, it 
had significantly improved the survival of DLBCL patients, thus altered previously 
understanding and prediction of clinical outcome. This leads to revision of IPI 
(Revised IPI). It identified 3 different prognostic groups and provided a better 
prediction of clinical outcome. Patients with zero factors have very good prognosis 
and more than 2 factors have poor prognosis (Laurie HS, 2007).  
 
Table 1.1 International Prognostic Index Interpretations 
 
Shimin Hu et al (2013) in their study showed DLBCL with Double Expression had 
clinicopathological features associated with aggressive clinical course. This group of patients 
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had significant extra nodal involvement, higher serum LDH level, and thus higher IPI 
score in comparison with non-Double Expression, which may translate into poorer 
adverse outcome and thus prognosis. However, B symptoms were not significantly 
rose in Double Expression group.  
 
1.5 Ann Arbor Staging System  
Ann Arbor Staging originally was developed for Hodgkin disease, but it serves as a 
basis for anatomic staging in non-Hodgkin Lymphomas as well (James OA, 2005). It 
helps clinician to stage the disease and determine the treatment plan in a more 
rational and objective way (WHO, 2008).  
This system divides patients into 4 stages based on localized disease, multiple site 
disease on one side of diaphragm, lymphatic disease on both sides of diaphragm and 
disseminated disease. Localized extra-nodal sites and spleen involvement are 
recognized by a subscript E and S respectively (James OA, 2005).  The definition of 
these stages listed in the table below.  
 
Table 1.2 Ann Arbor Stages and Features 
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Staging in non-Hodgkin Lymphoma can be done using history, physical examination, 
laboratory studies, and images (Computerized Tomography Scan and Magnetic 
Resonance Imaging), in addition to definitive proof of involvement of a particular site 
from biopsy. 
 
As mentioned at previously, DLBCL with double expression is associated with 
aggressive disease progression thus advanced stage of disease. This is true as 
mentioned by Shimin Hu et al (2013) in their study, which showed that Double 
Expression group had significantly higher number of patients diagnosed with Stage III 
and IV.  
 
1.6 Eastern Cooperative Oncology Group (ECOG) Score (Oken M, 1982) 
This is a score that attempts to sort patients to variable group based on their general 
well-being, daily activity and performance status. It serves in a more objective way, 
to quantify the quality of life of these patients. 
 
Table 1.3 ECOG Grade and Description 
Performance status of a patient is not solely based on the aggressiveness and stages 
of the disease. Study by Shimin Hu et al (2013) showed that ECOG status is poorly 
associated with Double Expression status.   
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1.7 Bone Marrow and CNS Infiltration 
Bone marrow aspiration and Trephine biopsy examination is vital in evaluation and 
staging of DLBCL at the time of diagnosis and after therapy. Iliac crest is considered 
the best spot for bone marrow biopsy. Biopsy specimens were studied for cellularity, 
hematological elements, extent of infiltration, histologic pattern and morphology of 
infiltration, reticulin fibrosis and other secondary changes (Suneet K, 2009).  
 
Central nervous system involvement in DLBCL is diagnosed by patients’ history, 
clinical examination, Imaging (CT scan and MRI) and CSF examination via lumbar 
puncture. CNS involvement is considered when there is meningeal infiltration 
showed in imaging or CSF showed positive cytology result (A Hollender, 2002).  
 
Both CNS and BM involvement is associated with poor prognosis. As DLBCL with 
Double expression is associated with advance and aggressive behavior of disease, 
one would expect the likely hood of involvement in this group. Literature review 
showed no available data at the time of study addressing these.  
 
1.8 Treatment Response 
The standard chemotherapy regimen for DLBCL is RCHOP, which consists of 
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone. The 
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regimen is given for 6 cycles with 21 days interval in between cycle. Interim 
assessments in the form of clinical examination and imaging studies (CT scan) are 
undertaken to decide for treatment responses. Cheson Criteria was used to define 
the following treatment response (Cheson BD, 2014): 
 Complete Remission (CR) is the disappearance of all evidence of diseases, 
which include regression of nodal mass to its normal size, regression of 
hepatosplenomegaly and cleared of bone marrow infiltration during the time 
of assessment.   
 Partial Response (PR) was considered when tumor mass or organ infiltration 
decreased by at least 50 % along with the disappearance of disease-related 
symptoms during the time of assessment. 
 
1.8.1 Complete Response  
Complete response is defined as patients who achieved complete remission upon 
completion of 6 cycles of chemotherapy. Shimin Hu et al noted DLBCL with double 
expression had significantly lower Complete Response rate (Shimin Hu, 2013). 
Double Expression does not response well with current chemotherapy regimen i.e. 
RCHOP.  
 
1.8.2 Early Response 
Identification of early response status during the interim assessment is of vital 
important in order to maximize the chances of second line or salvage chemotherapy 
success, avoid the unnecessary side effect of failed first line chemotherapy and 
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cutting down cost of treatment. In the Lugano criteria published in 2014 (Cheson BD, 
2014), PET-CT is recommended for staging as well as response assessment following 
therapy, as it is the most accurate imaging modality.  
 
PET-CT emerged as a reliable biomarker for assessing early response in DLBCL. It 
assesses tumor metabolic activity (via standard uptake volume-SUV), metabolic 
tumor volume (MTV) and metabolic tumor burden (MTB). Thus give rise to a better 
accuracy in detecting tumor aggressiveness as to compare to biopsy and may predict 
early treatment response as early as 1 week after chemotherapy (Xingchen Wu, 
2014).  
 
Besides the criteria as per defined based on PET/CT (which is not widely available), 
there are no standard universal criteria for Early Response. Thus, in this study, 
patients who achieved complete remission or partial remission during interim 
assessment are considered as early responder.  
 
Literature review showed no available data at the time of study addressing early 
response in DLBCL with double expression.  
 
1.9 Rationale of the Study  
DLBCL is a heterogeneous and complex disease. Its Double Expression is associated 
with poor response to standard treatment and thus may translate into poor 
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outcome/prognosis (Allison Rosenthal, 2016). Multiple studies had concluded that 
the median survivals of DLBCL with Double Expresser Phenotypes are often in 
months, with most reported to be no more than 1.5 years and with overall survivals 
at 3 or 5 years shorter than expected with usual DLBCL (Valera A, 2013). 
 
The DLBCL Double Expression statistic mentioned originate from oversea country, 
which may be compounded by factors such as ethnic group, lifestyle, dietary, 
geographic and etc. The prevalence differs among countries: Denmark (29%)( Green 
TM, 2012), United State (7-34%)( Allison Rosenthal, 2016), Canada (21-44%) 
(Johnson NA, 2012), Korea (10-16%)( Sehui Kim, 2016), Taiwan (2%)( ST Chang, 
2016), Japan (5%)( K Kawamoto, 2016) and etc.  
 
This study aims to produce our own set of statistic (as currently no such available) 
which may reflect local pictures and raise awareness on these phenotypes. With that 
we hope all DLBCL patient pathology samples should be tested for MYC, BCL2, and 
BCL6 expression. 
 
Knowing the aggressiveness of Double Expression DLBCL, this study will try to 
identify some added associated risk factors of Double Expression Phenotypes, which 
may lead to prediction of such phenotypes among DLBCL patients. These identifiable 
associated clinical risk factors may be used as a surrogate marker if were proven to 
be strongly significant, hence optimizing the additional specific laboratory testing on 
  18 
diagnostic tissue sample. With early prediction of Double Expression phenotypes, 
this may facilitate decision-making on best chemotherapy regimen option in the 
future.  
 
This study also assessed early response via interim CT scan, which is more applicable 
in most cancer centers in developing countries in which PET-CT are not widely 
available. Identification of early response status is of vital important in order to 
maximize the chances of second line or salvage chemotherapy success, avoid 
unnecessary suboptimal response to ineffective treatment and cutting down 
treatment cost. 
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CHAPTER 2: OBJECTIVES 
 
2.1 General Objective 
To determine the period prevalence of Double Expression DLBCL patients and its 
associated factors and treatment response in HUSM from 2004 to 2015.  
 
2.2 Specific Objective  
2.2.1 To determine the period prevalence of Double Expression of lymphoma 
protein MYC and BCL2/6 among Diffuse Large B-Cell Lymphoma patients in 
HUSM from 2004 to 2015.  
 
2.2.2 To determine the association between treatment response and this Double 
Expression among DLBCL patients in HUSM from 2004 to 2015? 
 Complete Response  
 Early Response 
 
2.2.3 To determine the various demographic and clinical factors that may be 
associated with this Double Expression among Diffuse Large B-Cell 
Lymphoma patients in HUSM from 2004 to 2015.  
 B symptoms  
 LDH 
 ECOG status  
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 Stage (Ann Arbor Staging System)  
 Extra-nodal Site  
 Age  
 Gender  
 CNS involvement  
 BM involvement  
 Revised IPI risk group 
 
 
2.3 Hypothesis   
Alternative Hypothesis  
There are significant associated risk factors and treatment response among Double 
Expression DLBCL patients in HUSM from 2004 to 2015. 
 
Null Hypothesis  
There are no significant associated risk factors and treatment response among 
Double Expression DLBCL patients in HUSM from 2004 to 2015. 
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CHAPTER 3: METHODOLOGY 
 
3.1 Study Design  
Retrospective record review.   
 
3.2 Study Population 
Patients who were newly diagnosed with DLBCL and treated in HUSM from year 
2004 until 2015. 
 
3.3 Study approval 
This study was approved by the Research and Ethic Committee, Universiti Sains 
Malaysia on 23rd March 2017. Study protocol number USM/JEPeM/16120584. 
 
3.4 Inclusion criteria (to all objectives) 
1. All patient that was newly diagnosed with DLBCL and treated in Hematology 
Unit, Hospital Universiti Sains Malaysia.  
2. Underwent at least 3 cycle of chemotherapy of RCHOP or R-mini CHOP. 
3. The availability of MYC, BCL2 and BCL6 results. 
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3.5 Exclusion criteria (to all objectives) 
1. Transformed DLBCL 
2. Relapsed or Progressive DLBCL 
3. Patient with other form of malignancy (double pathology) 
4. Patient did not receive RCHOP/R- mini CHOP.  
 
3.6 Sample Size Calculation 
Objective 1 
Sample size is based on prevalence of DLBCL double expression phenotypes  
N = [z / Δ ] 2 p ( 1 – p ) 
       P = prevalence of DLBCL Double Expression Phenotypes = 0.317-18 
       Z = 1.96 for 95% CI 
       Δ (precision) = 0.1 
       N = [ 1.96 / 0.1] 2 0.30 ( 1 – 0.30 )  
           = 81 
Missing data estimated to be 10% = 62 x 10% = 90 
The sample of 90 will be required at analysis stage.  
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Objective 2 
P0 is the probability of exposure to variables in DLBCL patients without Double 
Expression. These Variables were obtained from Shimin Hu et al (2013). 
P1 is an expert opinion about the probability of exposure to variables in DLBCL 
patients with Double Expression. 
 
The sample size calculated using Power and Sample Size Calculation version 3.0.10 
α = 0.05, power = 0.8, ratio (m) of 1:1; P0 = 0.84; P1 = 0.65, n = 81, Total n (adding 
10%) = 180 
A sample size of 181 DLBCL patients will be required for this study 
 
Objective 3 
P0 is the probability of exposure to variables in DLBCL patients without Double 
Expression. These Variables were obtained from Shimin Hu et al (2013). 
P1 is an expert opinion about the probability of exposure to variables in DLBCL 
patients with Double Expression. 
The samples size calculated using Power and Sample Size Calculations version 3.0.10 
α = 0.05; Power = 0.8; ratio (m) of 1:2 
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VARIABLES P0 P1 N 
TOTAL  N 
(Including 10% 
Missing Data) 
B symptoms 0.28 0.5 56 186 
LDH 0.58 0.8 52 173 
ECOG status 0.10 0.3 44 147 
Stage 
(Ann Arbor Staging System) 
0.43 0.7 39 130 
Extra-nodal Site 0.18 0.4 47 157 
Age (>60) 
There are no available data at the time of 
study design to estimate sample size based on 
the listed variables 
Gender  (Male) 
CNS involvement 
BM involvement 
IPI Risk Group 0.30 0.55 44 147 
Table 3.1 Sample Size Calculation 
 
A sample size of 186 DLBCL patients will be required for this study, assuming α = 
0.05, power = 0.8, ratio (m) of 1:2 and 10% of missing data.  
 
 
3.7 Patient Recruitment and Sampling Method 
Diffuse Large B-Cell Lymphoma patients diagnosed in HUSM from 2004 till 2015 were 
traced from medical record unit. Total of 278 patients were identified but only 222 
patients fulfilled inclusion and exclusion criteria. To be eligible, these subjects must 
be newly diagnosed with DLBCL and treated in Hematology Unit, Hospital Universiti 
Sains Malaysia, excluding transformed, relapsed or progressive DLBCL treated 
